Christine Schwimmer

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

François Raffi, Abdel G. Babiker, Laura Richert et al. · The Lancet · 2014 · 176 citations

Pharmacy, Infectious Diseases, Pharmacology +13

Antagonistic Interactions between Yeast [ <i>PSI</i> ⁺ ] and [ <i>URE3</i> ] Prions and Curing of [ <i>URE3</i> ] by Hsp70 Protein Chaperone Ssa1p but Not by Ssa2p

Christine Schwimmer, Daniel C. Masison · Molecular and Cellular Biology · 2002 · 173 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Long-term Mortality in HIV-Positive Individuals Virally Suppressed for &gt;3 Years With Incomplete CD4 Recovery

Frederik Neess Engsig, Robert Zangerle, François Dabis et al. · Clinical Infectious Diseases · 2014 · 172 citations · Full text

Public Health, Biostatistics, Infectious Diseases +14

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Andrew J. Pollard, Odile Launay, Jean‐Daniel Lelièvre et al. · The Lancet Infectious Diseases · 2020 · 170 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Robert Zangerle, Giota Touloumi, Josiane Warszawski et al. · Clinical Infectious Diseases · 2017 · 62 citations · Full text

Public Health, Health Sciences, Infectious Diseases +12